Review Article
Molecular Imaging-Guided Interventional Hyperthermia in Treatment of Breast Cancer
Table 1
Highlights of the genomic, clinical, and proteomic features of the four main subtypes of breast cancer.
| | Subtype | IHC markers [21] | DNA mutations [21] | mRNA expression [21] | Benefit from chemotherapy [22] | Outcome [22] |
| | Luminal A | ER+/HER2−: 87%; HER2+: 7%; TNBCs: 2%; and Ki67: low | PIK3CA (49%); TP53 (12%); GATA3 (14%); and MAP3K1 (14%) | High ER cluster; low proliferation | Low (0–5% pCR) | Good |
| | Luminal B | ER+/HER2−: 82%; HER2+: 15%; TNBCs: 1%; and Ki67: high | PIK3CA (32%); TP53 (32%); and MAP3K1 (14%) | Lower ER cluster; high proliferation | Intermediate (10–20% pCR) | Intermediate or poor |
| | Basal-like | ER+/HER2−: 10%; HER2+: 2%; TNBCs: 80%; and Ki67: high | PIK3CA (7%); TP53 (84%) | Basal signature; high proliferation | High (≥40% pCR) | Poor |
| | HER2E |
ER+/HER2−: 20%; HER2+: 68%; TNBCs: 9%; and Ki67: high | PIK3CA (42%); TP53 (75%); and PIK3R1 (8%) | HER2 amplicon signature; high proliferation | Intermediate (25–40% pCR) | Poor |
|
|
IHC: immunohistochemistry; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; +: positive; −: negative; TNBCs: triple-negative breast cancers; pCR: pathological complete response after neoadjuvant chemotherapy.
|
